These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11414062)

  • 1. Mycobacterium recombinant vaccines.
    Labidi AH; Estes RC; David HL; Bollon AP
    Tunis Med; 2001 Feb; 79(2):65-81. PubMed ID: 11414062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current status of Helicobacter pylori vaccines: a review.
    Kabir S
    Helicobacter; 2007 Apr; 12(2):89-102. PubMed ID: 17309745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
    Jennings R; Simms JR; Heath AW
    Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity to intracellular parasites--a focus for vaccine research and a challenge to immunization programmes.
    Harboe M
    Dev Biol Stand; 1998; 92():145-7. PubMed ID: 9554268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
    Igietseme JU; Eko FO; Black CM
    Expert Rev Vaccines; 2003 Feb; 2(1):129-46. PubMed ID: 12901604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock proteins as vaccine adjuvants in infections and cancer.
    Segal BH; Wang XY; Dennis CG; Youn R; Repasky EA; Manjili MH; Subjeck JR
    Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Opinion in Immunology. Vaccines. Introduction.
    Ertl HC; Lanzavecchia A
    Curr Opin Immunol; 2010 Jun; 22(3):355-7. PubMed ID: 20510596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of Chlamydia vaccines.
    Igietseme J; Eko F; He Q; Bandea C; Lubitz W; Garcia-Sastre A; Black C
    Expert Opin Drug Deliv; 2005 May; 2(3):549-62. PubMed ID: 16296774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlamydia vaccine candidates and tools for chlamydial antigen discovery.
    Rockey DD; Wang J; Lei L; Zhong G
    Expert Rev Vaccines; 2009 Oct; 8(10):1365-77. PubMed ID: 19803759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis.
    Faisal SM; Yan W; McDonough SP; Mohammed HO; Divers TJ; Chang YF
    Vaccine; 2009 Oct; 27(44):6129-36. PubMed ID: 19715780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
    Wozniak TM; Ryan AA; Triccas JA; Britton WJ
    Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
    Walcher P; Mayr UB; Azimpour-Tabrizi C; Eko FO; Jechlinger W; Mayrhofer P; Alefantis T; Mujer CV; DelVecchio VG; Lubitz W
    Expert Rev Vaccines; 2004 Dec; 3(6):681-91. PubMed ID: 15606353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.